For oral semaglutide, the percentage of patients with severe hypoglycemia was 1.4% with oral semaglutide and 0.8% with placebo in PIONEER 6 ( versus comparator groups, including other GLP-1RAs ( Real world data with respect to hypoglycemia are limited to a single observational cohort from Canada ( Thus, the risk of hypoglycemia appears to be low with subcutaneous and oral semaglutide by themselves, yet the risk is increased when combined with sulfonylurea and/or insulin therapy
The nationwide poll was conducted January 9-13, 2025 using the AmeriSpeak Panel, the probability-based panel of NORC at the University of Chicago
10.1371/journal.pone.0232053 53
The Blundell study quantified this effect: a 24 percent reduction in total daily energy intake and a 35 percent reduction in ad libitum lunch intake
When to talk to a healthcare provider Only take GLP-1s alongside the guidance of a healthcare provider, and with regular touchpoints where you can talk to that provider about your symptoms
A diet high in processed foods and added sugars can disrupt the delicate balance of the gut microbiome, leading to inflammation and oxidative stress